Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network
- PMID: 26259943
- PMCID: PMC4574275
- DOI: 10.4269/ajtmh.15-0007
Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network
Abstract
Antimalarial drugs are key tools for the control and elimination of malaria. Recent decreases in the global malaria burden are likely due, in part, to the deployment of artemisinin-based combination therapies. Therefore, the emergence and potential spread of artemisinin-resistant parasites in southeast Asia and changes in sensitivities to artemisinin partner drugs have raised concerns. In recognition of this urgent threat, the International Centers of Excellence for Malaria Research (ICEMRs) are closely monitoring antimalarial drug efficacy and studying the mechanisms underlying drug resistance. At multiple sentinel sites of the global ICEMR network, research activities include clinical studies to track the efficacies of antimalarial drugs, ex vivo/in vitro assays to measure drug susceptibilities of parasite isolates, and characterization of resistance-mediating parasite polymorphisms. Taken together, these efforts offer an increasingly comprehensive assessment of the efficacies of antimalarial therapies, and enable us to predict the emergence of drug resistance and to guide local antimalarial drug policies. Here we briefly review worldwide antimalarial drug resistance concerns, summarize research activities of the ICEMRs related to drug resistance, and assess the global impacts of the ICEMR programs.
© The American Society of Tropical Medicine and Hygiene.
References
-
- Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet. 2012;379:413–431. - PubMed
-
- Gosling RD, Okell L, Mosha J, Chandramohan D. The role of antimalarial treatment in the elimination of malaria. Clin Microbiol Infect. 2011;17:1617–1623. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U19 AI089676/AI/NIAID NIH HHS/United States
- U19AI089702/AI/NIAID NIH HHS/United States
- U19AI089680/AI/NIAID NIH HHS/United States
- 5U19AI089676/AI/NIAID NIH HHS/United States
- U19AI089672/AI/NIAID NIH HHS/United States
- U19AI089696/AI/NIAID NIH HHS/United States
- U19 AI089680/AI/NIAID NIH HHS/United States
- U19AI089681/AI/NIAID NIH HHS/United States
- U19AI089688/AI/NIAID NIH HHS/United States
- U19AI089683/AI/NIAID NIH HHS/United States
- R01 AI075045/AI/NIAID NIH HHS/United States
- U19 AI089681/AI/NIAID NIH HHS/United States
- U19 AI089674/AI/NIAID NIH HHS/United States
- U19 AI089696/AI/NIAID NIH HHS/United States
- U19AI089674/AI/NIAID NIH HHS/United States
- U19 AI089686/AI/NIAID NIH HHS/United States
- U19 AI089688/AI/NIAID NIH HHS/United States
- U19 AI089683/AI/NIAID NIH HHS/United States
- U19 AI089672/AI/NIAID NIH HHS/United States
- U19 AI089702/AI/NIAID NIH HHS/United States
- U19AI089686/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
